Genetic-guided Risk Assessment and Management of Thyroid Cancer

Mingzhao Xing

doi:10.1016/j.ecl.2018.11.007

Genetic-guided Risk Assessment and Management of Thyroid Cancer

Mingzhao Xing

School of Medicine

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

Original language	English (US)
Pages (from-to)	109-124
Number of pages	16
Journal	Endocrinology and metabolism clinics of North America
Volume	48
Issue number	1
DOIs	https://doi.org/10.1016/j.ecl.2018.11.007
State	Published - Mar 2019

Keywords

BRAF V600E mutation
Genetic molecular marker
Prognosis
RAS mutation
Risk stratification
TERT promoter Mutation
Thyroid cancer

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.ecl.2018.11.007

Cite this

@article{67c329f984e847a7aae452d3feed6b0e,

title = "Genetic-guided Risk Assessment and Management of Thyroid Cancer",

abstract = "Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.",

keywords = "BRAF V600E mutation, Genetic molecular marker, Prognosis, RAS mutation, Risk stratification, TERT promoter Mutation, Thyroid cancer",

author = "Mingzhao Xing",

note = "Funding Information: Funding Support: This work was supported by US National Institutes of Health grants R01CA215142 and R01CA189224 to M. Xing. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = mar,

doi = "10.1016/j.ecl.2018.11.007",

language = "English (US)",

volume = "48",

pages = "109--124",

journal = "Endocrinology and metabolism clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Genetic-guided Risk Assessment and Management of Thyroid Cancer

AU - Xing, Mingzhao

PY - 2019/3

Y1 - 2019/3

N2 - Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

AB - Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

KW - BRAF V600E mutation

KW - Genetic molecular marker

KW - Prognosis

KW - RAS mutation

KW - Risk stratification

KW - TERT promoter Mutation

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85060876395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060876395&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2018.11.007

DO - 10.1016/j.ecl.2018.11.007

M3 - Review article

C2 - 30717896

AN - SCOPUS:85060876395

SN - 0889-8529

VL - 48

SP - 109

EP - 124

JO - Endocrinology and metabolism clinics of North America

JF - Endocrinology and metabolism clinics of North America

IS - 1

ER -

Genetic-guided Risk Assessment and Management of Thyroid Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this